← boardnext 2026-09-30
CURX
Cantex Pharmaceuticalsdistress 8/10 · high distress / dilution risk$0.20-1%today-98% from 52w high
Lead: ulcerative colitis · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$4M
Runway
0.3 yrs
Shares 1y
+2%
Price & events
-45.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-8.2%
1W
-27.0%
1M
-54.8%
3M
-44.1%
6M
—
1Y
—
2Y
—
5Y
-95.0%
All
Overview
- Market Cap
- $5.68M
- Volume
- 16.00K
- 52 Week Range
- $0.20 – $9.16
- Total Shares
- 28.36M
- Float Shares
- 8.91M
- Short %
- 0.67%
- % Held by Insiders
- 67.81%
- % Held by Institutions
- 0.00%
- RVOL
- 0.19x
Pipeline stages · 1 programs
Azeliragon
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-30 Estimated 50% readout ~2026-11-14 | Phase 2 | Azeliragon | Glioblastoma | — | active not recruiting |
Catalyst news & presentations · 1
- fourth quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)Phyto-N · Planned IND submission to FDA for Phyto-N for ulcerative colitis.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — ulcerative colitis
- LLYELI LILLY & Co$1094.4B · D3
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- PFEPFIZER INC$142.2B · D3
- TKPHFTAKEDA PHARMACEUTICAL CO LTD$53.7B · D1
- SNYSanofi$52.5B · D1
- AAVXFAbivax S.A.$10.9B · D1
- PTGXProtagonist Therapeutics, Inc$8.6B · D0
- SYRESpyre Therapeutics, Inc.$8.5B · D6
- ODTXOdyssey Therapeutics, Inc.$908M · D3
Recent news
- 2026-07-20CURX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
- 2026-07-09Curanex Pharmaceuticals (CURX) Edges Higher on Modest Gains, Testing Key Resistance at $0.23 - Fibonacci Fan - dars.gov.et
- 2026-07-01Curanex Pharmaceuticals (CURX) Edges Higher as Bulls Defend Key $0.26 Support Level - Factor Rotation - dars.gov.et
- 2026-06-29Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Canada
- 2026-05-07Curanex Pharmaceuticals receives extension from Nasdaq to regain bid price compliance - Investing.com
- 2026-04-17Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX - Business Wire
- 2026-04-08Five critically ill patient accounts inform Curanex's cachexia focus - Stock Titan
- 2026-02-25Curanex Provides Operational Update on Key Regulatory Milestones - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.